BARDA awards Cempra up to $58M for antibiotics

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded Cempra Inc. (NASDAQ:CEMP) up to $58 million to develop solithromycin to treat infections in pediatric populations and infections caused by bioterror threat pathogens. Cempra will receive $17.7 million for an initial two-year period and up to $58 million if the contract is extended for the full five years. ...